Related Experiment Video

Updated: Nov 4, 2025

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

24.9K

Hyperbilirubinemia and Asphyxia in Children With Dyskinetic Cerebral Palsy

Arushi Gahlot Saini1, Naveen Sankhyan2, Prahbhjot Malhi3

  • 1Associate Professor, Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Pediatric Neurology
|May 23, 2021
PubMed

Insights

Dyskinetic cerebral palsy (DCP) in children is often caused by hyperbilirubinemia, leading to severe motor impairments. This condition is linked to specific neurological damage patterns, highlighting the need for early diagnosis and intervention in affected infants.

Area of Science:

  • Pediatric Neurology
  • Neurodevelopmental Disorders
  • Clinical Neuroscience

Background:

  • Dyskinetic cerebral palsy (DCP) is a significant motor disability in children.
  • Understanding the etiological factors and clinical presentations of DCP is crucial for effective management.
  • Hyperbilirubinemia and perinatal asphyxia are key etiological considerations in DCP.

Purpose of the Study:

  • To investigate the clinical, etiologic, and radiological characteristics of DCP in children.
  • To compare the distinct features and neurological involvement between hyperbilirubinemia-induced and perinatal asphyxia-induced DCP.
  • To identify key differences in brain imaging findings and clinical outcomes based on the etiology of DCP.

Main Methods:

  • A cross-sectional, observational study involving 65 children aged 1-14 years diagnosed with DCP.
  • Evaluation of clinical presentation, etiological factors (hyperbilirubinemia, perinatal asphyxia), and radiological findings.
  • Statistical comparison of clinical and radiological characteristics between hyperbilirubinemia and perinatal asphyxia subgroups.

Main Results:

  • Hyperbilirubinemia (66%) and perinatal asphyxia (29%) were the primary causes of DCP in the evaluated cohort.
  • Children with hyperbilirubinemia-related DCP showed significant motor delay and upward gaze palsy compared to the asphyxia group.
  • Radiological analysis revealed distinct patterns of brain involvement: globus pallidi and subthalamic nuclei in hyperbilirubinemia, and putamen, thalamus, and periventricular white matter in asphyxia.

Conclusions:

  • Dyskinetic cerebral palsy is a dominant form of CP in term-born infants, characterized by dystonia, developmental delay, and motor deficits.
  • Hyperbilirubinemia emerges as a leading cause of DCP, associated with specific clinical features like motor delay and gaze abnormalities.
  • Distinct patterns of basal ganglia and white matter involvement on neuroimaging differentiate hyperbilirubinemia-induced DCP from that caused by perinatal asphyxia.
Abstract

Keywords:
BINDBasal gangliaChoreoathetosisDyskinetic cerebral palsyDystoniaHyperbilirubinemiaJaundiceKernicterus

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.5K
A Swine Model of Neonatal Asphyxia10:36

A Swine Model of Neonatal Asphyxia

Published on: October 11, 2011

14.5K

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
461
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
49
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
437
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
49
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
598
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
311